Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103007 | 0.93 | CNR1 (0.60) | CNR1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL5113066 | 0.85 | CNR1 (0.53) | CNR1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL5105716 | 0.83 | LMNA (0.52) | CNR1LMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5106047 | 0.83 | CNR1 (0.57) | CNR1SMN1; SMN2MAPTALDH1A1MAPK1 | |
| SCHEMBL5098463 | 0.83 | CNR1 (0.53) | CNR1LMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5099479 | 0.80 | TSHR (0.59) | CNR1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL5110891 | 0.79 | CNR1 (0.57) | CNR1 | |
| SCHEMBL5111599 | 0.77 | CNR1 (0.54) | CNR1 | |
| SCHEMBL5106083 | 0.73 | CNR1 (0.54) | CNR1 | |
| SCHEMBL5111398 | 0.73 | CNR1 (0.59) | CNR1KDM4ETP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320978-B2 | Oxazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | claimed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1716142-A2 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEROF | Sanofi-Aventis (FR) | 2006-11-02 | — | — | EP | claimed |
| WO-2005080357-A2 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEROF | SANOFI-AVENTIS (FR) | 2005-09-01 | — | — | WO | claimed |
| US-7320978-B2 | Oxazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-01-22 | — | — | US | disclosed |
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
| EP-1716142-A2 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEROF | Sanofi-Aventis (FR) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080357-A2 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEROF | SANOFI-AVENTIS (FR) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | OXA1L, ARG2, CYP3A7 | CNR1 246/4885LMNA 3695/4885SMN1; SMN2 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.